SEALSQ is undervalued, with a forward EV/Sales ratio of ~4x for 2027 and strong growth prospects. Recent acquisitions, including Miraex and IC'Alps, strategically strengthen LAES's supply chain and position in quantum and medtech sectors. The backlog for 2026-2028 stands at $200 million, supporting revenue projections of $50 million–$70 million by 2027 and the potential for upward estimate revisions.